Keywords: trigen, tgn, shows, promise, hemodialysis, german, drug

Trigen's TGN 255 shows promise in hemodialysis

Article | 24 July 2006

Print This

German drug developer Trigen says that data from a Phase II trial of TGN 255, a direct thrombin inhitor intended for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in